|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of May 1, 2025
|
|
|---|---|---|---|---|---|---|
| Cash | ||||||
| Deferred offering costs | ||||||
| Prepaid expenses | ||||||
| Total Current Assets | ||||||
| Marketable securities held in Trust Account | ||||||
| Total Assets | ||||||
| Current Liabilities | ||||||
| Notes payable to related party | ||||||
| Accrued expenses and other current liabilities | ||||||
| Total Current Liabilities | ||||||
| Deferred underwriting fee payable | ||||||
| Total Liabilities | ||||||
| Commitments and Contingencies (Note 6) | ||||||
| Ordinary shares subject to possible redemption: 6,900,000 shares at redemption value of approximately $10.45 per share at June 30, 2026 and $10.27 per share at December 31, 2025 | ||||||
| Shareholders' Deficit | ||||||
| Ordinary shares, $0.0001 par value, 500,000,000 shares authorized, 2,005,000 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively(1) | ||||||
| Additional paid-in capital | ||||||
| Accumulated deficit | ||||||
| Total Shareholders' Deficit | ||||||
| Total Liabilities and Shareholders' Deficit |
Loading...
